ATANA Stock Overview
Provides biologically related information to customers in developing pharmaceutical drugs primarily in Europe and Asia.
| Snowflake Score | |
|---|---|
| Valuation | 1/6 |
| Future Growth | 0/6 |
| Past Performance | 0/6 |
| Financial Health | 3/6 |
| Dividends | 0/6 |
Attana AB Competitors
Price History & Performance
| Historical stock prices | |
|---|---|
| Current Share Price | SEK 0.081 |
| 52 Week High | SEK 0 |
| 52 Week Low | SEK 0 |
| Beta | 0.22 |
| 11 Month Change | -1.22% |
| 3 Month Change | -1.22% |
| 1 Year Change | -66.11% |
| 33 Year Change | -91.96% |
| 5 Year Change | -89.73% |
| Change since IPO | -78.91% |
Recent News & Updates
Recent updates
Shareholder Returns
| ATANA | SE Life Sciences | SE Market | |
|---|---|---|---|
| 7D | 2.5% | 1.3% | 1.6% |
| 1Y | -66.1% | 81.3% | 25.5% |
Return vs Industry: ATANA underperformed the Swedish Life Sciences industry which returned 79.8% over the past year.
Return vs Market: ATANA underperformed the Swedish Market which returned 24.3% over the past year.
Price Volatility
| ATANA volatility | |
|---|---|
| ATANA Average Weekly Movement | 8.0% |
| Life Sciences Industry Average Movement | 8.5% |
| Market Average Movement | 5.6% |
| 10% most volatile stocks in SE Market | 11.6% |
| 10% least volatile stocks in SE Market | 3.2% |
Stable Share Price: ATANA has not had significant price volatility in the past 3 months.
Volatility Over Time: ATANA's weekly volatility has decreased from 13% to 8% over the past year.
About the Company
| Founded | Employees | CEO | Website |
|---|---|---|---|
| 2002 | 10 | Teodor Aastrup | www.attana.com |
Attana AB provides biologically related information to customers in developing pharmaceutical drugs primarily in Europe and Asia. The company offers analytical biosensor which allows studies on molecular interactions between proteins, DNA, and carbohydrates, as well as interactions to cells cultured; contract research services; and attana virus analytics. It serves academic institutions, biotech companies, and pharma companies.
Attana AB Fundamentals Summary
| ATANA fundamental statistics | |
|---|---|
| Market cap | SEK 34.88m |
| Earnings (TTM) | -SEK 12.18m |
| Revenue (TTM) | SEK 6.54m |
5.3x
P/S Ratio-2.9x
P/E RatioIs ATANA overvalued?
See Fair Value and valuation analysisEarnings & Revenue
| ATANA income statement (TTM) | |
|---|---|
| Revenue | SEK 6.54m |
| Cost of Revenue | SEK 1.43m |
| Gross Profit | SEK 5.12m |
| Other Expenses | SEK 17.30m |
| Earnings | -SEK 12.18m |
Last Reported Earnings
Jun 30, 2024
Next Earnings Date
n/a
| Earnings per share (EPS) | -0.028 |
| Gross Margin | 78.20% |
| Net Profit Margin | -186.17% |
| Debt/Equity Ratio | 18.8% |
How did ATANA perform over the long term?
See historical performance and comparison